AlphAIalphai — Financial news for AI agents
marketscreener.comAUG 31 min read$SYK

UBS Adjusts Stryker Price Target to $382 From $400, Maintains Buy Rating

UBS lowered its price target on Stryker (SYK) to $382 from $400 while keeping a Buy rating, according to the note cited in the article. The stock is shown trading around $341.20 at market close on Aug. 3, 2026.

Original reporting
marketscreener.com
Published Aug 3, 2026, 2:18 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 4, 2026, 4:14 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$SYK
Neutral
medium confidence
Mentioned
$SYK
Relevance
4/10
alphai data visualization · based on marketscreener.com
Decision brief

The 30-second read

$SYKNeutralLow
01

Why it matters

For trading, the main actionable element is the PT cut, but the text lacks any new SYK-specific operational or financial datapoint.

02

Market read

This is primarily a valuation narrative update from one analyst, not a new fundamental catalyst.

03

What to watch

Traders may care more about consensus PT changes, upcoming earnings date, and any other simultaneous analyst actions not included in this snippet.

Relevance 4/10Novelty 4/10Timing: published during market hours, but no new SYK fundamentals are disclosed

Background

The piece is a sell-side note summary stating UBS lowered its Stryker price target while keeping a Buy rating.

Company-level read

Ticker impact

$SYKNeutralMedium confidence
Context

UBS adjusted Stryker’s price target to $382 from $400 while maintaining a Buy rating, signaling a valuation view change.

Expected impact

Likely limited near-term impact unless traders treat the PT change as a catalyst; follow-through depends on broader analyst consensus.

Evidence & confidence

The article provides only the PT revision and rating maintenance, with no earnings, guidance, or operational news disclosed.

Market effects

Sector

Minimal, since it is a single-analyst target change with no sector-wide catalyst described.

Regional

None indicated beyond general US equity sentiment.

Global

None indicated.

Counterpoint

What could challenge this read

A lower PT with the same Buy rating may reflect valuation compression rather than deteriorating fundamentals, so the market may discount it.

Key entities

  • company
    Stryker

    Subject of the analyst price-target adjustment and maintained Buy rating.

  • analyst_firm
    UBS

    Brokerage issuing the price target change.

Read at source← All news

Related articles

AUG 4
$SYKMedAI 8/10

Stryker (SYK) Q2 2026 Earnings Call Transcript

Stryker (SYK) reported Q2 2026 adjusted EPS of $3.69, up 17.9% year over year, with organic net sales up 9% and adjusted gross margin at 66%. Management cited recovery from a prior cybersecurity incident and higher production. Full-year organic net sales guidance is 8.3% to 9.3%, and adjusted EPS guidance is $14.95 to $15.10.

fool.com6 min
JUL 31
$SYKMedAI 8/10

Why Stryker (SYK) Shares Are Plunging Today

Stryker (SYK) shares fell about 7.3% in the morning after the company reported Q2 results. Revenue rose 9.4% year over year to $6.59 billion, but organic growth of about 9% met only Wall Street expectations and missed forecasts. Adjusted earnings were $3.69 per share, beating estimates by 5.8%, and guidance was slightly raised.

financialcontent.com5 min
JUL 31
$SYKMedAI 8/10

Stryker nets $6.6bn revenue in Q2; highlights resilience following cyberattack

Stryker has reported Q2 revenues of $6.6bn, denoting a 9.4% rise year-over-year (YoY), with the company's CEO lauding its "significant progress" in recovering since its global operations were disrupted by an cyberattack in March. Following the results, Stryker is tweaking its 2026 outlook at the low end, with earnings now projected to land in the $14.95 to $15.10 per share range, up from $14.90 to $15.10 previously.

yahoo.com4 min
JUL 31
$SYKMedAI 8/10

Stryker (SYK) Q2 2026 Earnings Call Transcript

Thursday, July 30, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chair and Chief Executive Officer - Kevin A. Lobo Chief Financial Officer - Preston Wells Vice President of Investor Relations - Nick Mead TAKEAWAYS Organic Net Sales -- 9% growth, reflecting recovery from a previous cybersecurity incident and increased production to meet demand. Adjusted EPS -- $3.69, a 17.9% increase from the same quarter last year, reflecting improved gross margins and operational execution.

fool.com6 min
JUL 31
$SYKHighAI 9/10

Stryker Q2 adj. EPS hits $5.75, beating $3.49 estimate

Stryker (NYSE: SYK) reported second-quarter 2026 adjusted earnings per share of $5.75, surpassing analyst consensus estimates of $3.49 by 64.76 percent. This result marks an 83.71 percent year-over-year increase from $3.13 in the prior-year period. Consolidated net sales rose 9.42 percent to $6.589 billion, narrowly exceeding the $6.579 billion estimate. The strong performance reflects robust operational execution and expanded margins despite modest revenue growth.

scanx.trade6 min
JUL 30
$SYKMed

SYK: Strong Q2 sales and EPS growth, with robust outlook and narrowed full-year guidance

Less than 1 min read Delivered 9% organic sales growth and 17.9% adjusted EPS growth year-over-year, overcoming supply disruptions and a prior cybersecurity incident. Narrowed full-year guidance reflects strong demand, robust backlog, and confidence in production ramp and capital order fulfillment. Based on Stryker Corporation [SYK] Q2 2026 Audio Transcript — Jul. 30 2026 Disclaimer This is an AI-generated summary and may contain inaccuracies.

tradingview.com1 min